MX2015012936A - Formulacion de dosificacion oral solida del inhbidor de hcv en estado amorfo. - Google Patents

Formulacion de dosificacion oral solida del inhbidor de hcv en estado amorfo.

Info

Publication number
MX2015012936A
MX2015012936A MX2015012936A MX2015012936A MX2015012936A MX 2015012936 A MX2015012936 A MX 2015012936A MX 2015012936 A MX2015012936 A MX 2015012936A MX 2015012936 A MX2015012936 A MX 2015012936A MX 2015012936 A MX2015012936 A MX 2015012936A
Authority
MX
Mexico
Prior art keywords
oral dosage
solid oral
dosage forms
compound
amorphous state
Prior art date
Application number
MX2015012936A
Other languages
English (en)
Other versions
MX364431B (es
Inventor
Zeren Wang
Chitra Telang
Li Zhong
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2015012936A publication Critical patent/MX2015012936A/es
Publication of MX364431B publication Critical patent/MX364431B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Abstract

En la presente se describen formas de dosificación oral sólida que contienen el compuesto (1) o una sal de este aceptable desde el punto de vista farmacéutico: (ver Fórmula) en donde el compuesto (1) está en estado amorfo. También se describen formas de dosificación oral sólida que comprenden una composición de compuesto (1) en estado amorfo y uno o más excipientes aceptables desde el punto de vista farmacéutico. El compuesto (1) es un inhibidor específico de la resina proteasa NS3/4A del virus de hepatitis C (HCV). Por lo tanto, en la presente también se describen métodos para usar las formas de dosificación oral sólida en el tratamiento de la infección por HCV. También se describen procesos para la fabricación de formas de dosificación oral sólida.
MX2015012936A 2013-03-15 2014-03-13 Formulación de dosificación oral sólida del inhibidor de hcv en estado amorfo. MX364431B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791093P 2013-03-15 2013-03-15
PCT/US2014/026028 WO2014151575A1 (en) 2013-03-15 2014-03-13 Solid oral dosage formulation of hcv inhibitor in the amorphous state

Publications (2)

Publication Number Publication Date
MX2015012936A true MX2015012936A (es) 2015-12-03
MX364431B MX364431B (es) 2019-04-26

Family

ID=50771327

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012936A MX364431B (es) 2013-03-15 2014-03-13 Formulación de dosificación oral sólida del inhibidor de hcv en estado amorfo.

Country Status (16)

Country Link
US (1) US9732076B2 (es)
EP (1) EP2968154B1 (es)
JP (1) JP6130585B2 (es)
KR (1) KR20150129005A (es)
CN (1) CN105228593B (es)
AU (1) AU2014233705C1 (es)
BR (1) BR112015021692A2 (es)
CA (1) CA2903831A1 (es)
CL (1) CL2015002681A1 (es)
EA (1) EA032322B1 (es)
IL (1) IL240840A0 (es)
MX (1) MX364431B (es)
PH (1) PH12015502258B1 (es)
SA (1) SA515361071B1 (es)
UA (1) UA116237C2 (es)
WO (1) WO2014151575A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004099442A (ja) * 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
PT1654261E (pt) * 2003-05-21 2008-01-18 Boehringer Ingelheim Int Compostos inibidores da hepatite c
BRPI0511900A (pt) 2004-06-08 2008-01-22 Vertex Pharma composições farmacêuticas
AU2007226983A1 (en) 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
CA2699335A1 (en) 2007-10-19 2009-04-23 Abbott Gmbh & Co. Kg. Solid dispersion product containing n-aryl urea-based compound
PE20110388A1 (es) * 2008-09-16 2011-07-01 Boehringer Ingelheim Int Formas cristalinas de un derivado de peptido como inhibidores de hcv
SG2014008981A (en) * 2009-02-27 2014-04-28 Ortho Mcneil Janssen Pharm Amorphous salt of a macrocyclic inhibitor of hcv
CA2767692C (en) * 2009-07-07 2017-03-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition for a hepatitis c viral protease inhibitor
NZ605440A (en) * 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
EP2797586A1 (en) * 2011-12-29 2014-11-05 AbbVie Inc. Solid compositions comprising an hcv inhibitor

Also Published As

Publication number Publication date
KR20150129005A (ko) 2015-11-18
PH12015502258A1 (en) 2016-02-01
IL240840A0 (en) 2015-10-29
UA116237C2 (uk) 2018-02-26
WO2014151575A1 (en) 2014-09-25
EA201500932A1 (ru) 2016-03-31
CN105228593A (zh) 2016-01-06
JP2016514156A (ja) 2016-05-19
EP2968154B1 (en) 2020-06-17
CL2015002681A1 (es) 2016-04-08
BR112015021692A2 (pt) 2017-07-18
SA515361071B1 (ar) 2017-11-29
PH12015502258B1 (en) 2016-02-01
CA2903831A1 (en) 2014-09-25
EA032322B1 (ru) 2019-05-31
US9732076B2 (en) 2017-08-15
AU2014233705C1 (en) 2019-10-10
MX364431B (es) 2019-04-26
JP6130585B2 (ja) 2017-05-17
EP2968154A1 (en) 2016-01-20
CN105228593B (zh) 2018-08-28
US20160185767A1 (en) 2016-06-30
AU2014233705B2 (en) 2019-01-03
AU2014233705A1 (en) 2015-09-10

Similar Documents

Publication Publication Date Title
WO2017075629A3 (en) Wee 1 kinase inhibitors and methods of making and using the same
EA201792116A1 (ru) Ингибитор янус-киназы
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
EA201791955A1 (ru) ИНГИБИТОРЫ TGF-β
UA117518C2 (uk) 6-конденсовані гетероарилдигідропіримідини для лікування та профілактики зараження вірусом гепатиту b
EA201491824A1 (ru) Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
MX2017008386A (es) Administración específica del sitio de un inhibidor de btk.
GEP20156263B (en) Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for production and usage thereof
EA201490650A1 (ru) Фармацевтические композиции
CO2017000980A2 (es) Compuestos derivados de imidazo[1,2-b]piridazin-2-carboxamida e imidazo[1,2- b]piridazin-2-ilmetanona activos como inhibidores selectivos de la fosfodiesterasa 4a (pde4a)
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
EA201490653A1 (ru) Производные эстра-1,3,5(10),16-тетраен-3-карбоксамида, способ их получения, содержащие их фармацевтические препараты, а также их применение для получения лекарственных средств
MX2015011770A (es) Inhibidores dipeptídicos y tripeptídicos de epoxi cetona proteasa.
TN2015000574A1 (en) Compounds and compositions as inhibitors of mek
WO2012092409A3 (en) Macrocyclic hepatitis c serine protease inhibitors
MY201325A (en) Substituted nitrogen containing compounds
WO2015160907A3 (en) Potent and selective inhibitors of hepatitis c virus
EA201891239A1 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
WO2014116772A3 (en) Squaric derivatives for the treatment of hepatitis c
MX364431B (es) Formulación de dosificación oral sólida del inhibidor de hcv en estado amorfo.
WO2014160177A3 (en) Quinazoline inhibitors of pi3k
MX2021002885A (es) Método de manufactura de una forma sólida de un inhibidor de bromodominio de proteínas con bromodominio y dominio extraterminal (bet).
AR088735A1 (es) Compuestos de tienopirimidina que son inhibidores de canal de potasio
AU2016248387A8 (en) Preparation and use of kinase inhibitor
MX2017009863A (es) Agente preventivo y/o terapeutico de enfermedad inmune.

Legal Events

Date Code Title Description
FG Grant or registration